ArticleSpringerPlus2016
Rifampin-warfarin interaction in a mitral valve replacement patient receiving rifampin for infective endocarditis: a case report.
Article in SpringerPlus, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and Perspectives.Pharmaceutics · 2026Review
- Real-World Evaluation of the Interaction Between Rifampicin and Warfarin: A Retrospective Observational Study.Advances in pharmacological and pharmaceutical sciences · 2025Article
- Review
- Article
- Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation.BMC cardiovascular disorders · 2023Article
- Validation of medical prescriptions’ suitability on patients with heart diseaseArchivos de cardiologia de Mexico · 2022Article
- A case series of the rifampin-warfarin drug interaction: focus on practical warfarin management.European journal of clinical pharmacology · 2021Article
- Effect of rifampicin on anticoagulation of warfarin: A case report.World journal of clinical cases · 2021Article
- Genetic Polymorphism Effect on Warfarin-Rifampin Interaction: A Case Report and Review of Literature.Pharmacogenomics and personalized medicine · 2021Article
- Potential Metabolic Drug-Drug Interaction ofFrontiers in pharmacology · 2018Article
- Successful Anticoagulation With Warfarin After Switching From Rifampin to Rifabutin.Journal of primary care & community healthArticle
- Preemptive Dose Adjustment Effect on the Quality of Anticoagulation Management in Warfarin Patients With Drug Interactions: A Retrospective Cohort Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWarfarin therapy is associated with many drug interactions that may cause a significant alteration in its anticoagulant effect. Rifampin is a widely used antimicrobial that has major interactions with several medications including warfarin due to its strong P-glycoprotein and liver enzyme inducer activity especially on CYP2C9, CYP3A4, CYP1A2 and CYP2C19. PRESENTATION: We report a case of a 34-year-old Srilankan female chronically treated with warfarin for her mitral valve replacement. The patient developed infective endocarditis and was started on a 6-week treatment with rifampin along with other antibiotics. Warfarin dose was increased from 52.5 to 210 mg/week over the course of the rifampin therapy, however, the INR remained subtherapeutic throughout the whole period and reached 2.4 by the end of rifampin therapy. DISCUSSION AND EVALUATION: Anticoagulation management was challenging in the period following the end of rifampin therapy as well, and multiple dose adjustments starting with an increase and followed by reduction were required till she was stable on an 80 mg/week warfarin dose 5 weeks post-rifampin therapy.
conclusionOur findings suggest the importance of close monitoring of warfarin therapy during and after the use of rifampin to minimize the risks of under and over-anticoagulation and improve the safety and efficacy of warfarin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.